Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Sara S Kornfeld-SyllaThe Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA. saraks@mit.edu.ORCID http://orcid.org/0009-0003-6027-9453
Cigdem GelegenWolfson Sensory, Pain and Regeneration Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Francesca A ChalonerWolfson Sensory, Pain and Regeneration Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0003-2707-4539
Maia LeeThe Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
Mark F BearThe Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA. mbear@mit.edu.ORCID http://orcid.org/0000-0002-9903-2541
Funding
Neurophysiological and acute pharmacological studies in FXS patientsU54HD082008 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI HUBER, KIMBERLY M. · 2014 to 2019
$9.8M
Translational medicine and mechanistic studies of brain neurophysiology in Fragile X SyndromeU54HD104461 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI HUBER, KIMBERLY M. · 2020 to 2024
$8.1M
Behavioral Consequences and cellular substrates of plasticity in visual cortexR01EY023037 · NEI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BEAR, MARK F · 2013 to 2025
$6.0M
Translational Post-doctoral Training in NeurodevelopmentT32MH112510 · NIMH · BOSTON CHILDREN'S HOSPITAL · PI DAVID C GLAHN, CHARLES Alexander NELSON · 2017 to 2026
$2.6M
Neural Markers of Language Development in Fragile X Syndrome and Autism Spectrum DisorderK23DC017983 · NIDCD · BOSTON CHILDREN'S HOSPITAL · PI WILKINSON, CAROL LEE · 2020 to 2024
$859k
Electrophysiological Biomarkers of Neurocognitive Deficits in Fragile X SyndromeK23HD101416 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI SCHMITT, LAUREN · 2020 to 2024
$617k
Pathophysiology and treatment of fragile X and related disordersR21NS123499 · NINDS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BEAR, MARK F · 2022 to 2023
$427k
Network mechanisms underlying core behavioral features in Fragile X SyndromeF31HD113221 · NICHD · UNIVERSITY OF OKLAHOMA · PI NORRIS, JORDAN · 2024 to 2024
$43k
National Science Foundation (NSF) GRFPNEI NIH HHS R01 EY023037NICHD NIH HHS F31 HD113221NICHD NIH HHS K23 HD101416NICHD NIH HHS U54 HD082008NICHD NIH HHS U54 HD104461NIDCD NIH HHS K23 DC017983NIMH NIH HHS T32 MH112510NINDS NIH HHS R21 NS123499RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/S008276/1Simons Foundation SFARI 575135U.S. Department of Health & Human Services | National Institutes of Health (NIH) 1K23DC017983-01A1U.S. Department of Health & Human Services | National Institutes of Health (NIH) 1T32MH112510U.S. Department of Health & Human Services | National Institutes of Health (NIH) F31 HD113221-01A1U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01EY023037U.S. Department of Health & Human Services | National Institutes of Health (NIH) R21NS123499U.S. Department of Health & Human Services | National Institutes of Health (NIH) U54HD082008U.S. Department of Health & Human Services | National Institutes of Health (NIH) U54HD104461Wellcome Trust
6 · The paper itself
Abstract
Predicting clinical therapeutic outcomes from animal studies using conserved electrophysiological phenotypes could facilitate developing treatments for neuropsychiatric disorders. Alpha oscillations in human resting-state electroencephalogram recordings are altered in many disorders, but whether these disruptions exist in mouse models is unknown. Here, we employed a uniform analytical method to show in males with fragile X syndrome (FXS) that alpha oscillations in humans and alpha-like oscillations in the visual cortex of Fmr1
Indexed as
Alpha RhythmFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeVisual CortexAdultAnimalsBaclofenDisease Models, AnimalElectroencephalographyHumansInterneuronsMaleMiceMice, Inbred C57BLMice, KnockoutBaclofenFMR1 protein, humanFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
A human electrophysiological signature of Fragile X pathophysiology is shared in V1 of Fmr1 · full record | Socratic